Marqeta Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Marqeta Inc trades at $18 (market cap $1.82B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.71 (market cap $2.27B). The key difference: SELLAS Life Sciences Group Inc. Common Stock is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Marqeta Inc nearer its low. Which is the better fit depends on your goals.
| MQ | SLS | |
|---|---|---|
Market Cap | $1.82B | $2.27B |
Volume | 1,126,466 | 4,179,659 |
Sector | Technology | Health |
52-Week High | $20.32 | $15.46 |
52-Week Low | $15.04 | $1.39 |
Typical Hold Time | 44 Days | — |
Enterprise Value | $1.13B | $2.14B |
Signals from Pluang's Aura AI — not financial advice
Marqeta (MQ) trades at $17.86, up 4.69% with a bullish technical outlook. The company shows improving fundamentals with three consecutive quarterly earnings beats and positive cash flow generation in 2025. Recent partnerships with BVNK for stablecoin cards and Google for kids' wallets highlight strategic growth initiatives. However, valuation remains elevated with a P/E of 193.83 and EV/EBITDA of 54.37 despite modest profitability metrics.
MQ presents a mixed investment case with strong operational momentum but premium valuation. The stock offers growth potential through expanding payment partnerships and product innovation, though faces risks from contract renewals and competitive pressure. Analyst consensus at $11.38 suggests caution despite recent positive earnings revisions and institutional interest in the fintech sector.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →